Lite Strategy, Inc. (LITS) - Total Liabilities
Based on the latest financial reports, Lite Strategy, Inc. (LITS) has total liabilities worth $1.07 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LITS net asset momentum to track the company's year-over-year net asset growth rate.
Lite Strategy, Inc. - Total Liabilities Trend (2021–2025)
This chart illustrates how Lite Strategy, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Lite Strategy, Inc. Competitors by Total Liabilities
The table below lists competitors of Lite Strategy, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BioSmart Co.Ltd
KQ:038460
|
Korea | ₩109.14 Billion |
|
Sentien Printing Factory Co Ltd
TWO:8410
|
Taiwan | NT$384.38 Million |
|
Playside Studios Ltd
AU:PLY
|
Australia | AU$14.74 Million |
|
Loop Industries Inc
NASDAQ:LOOP
|
USA | $18.14 Million |
|
Nexam Chemical Holding AB
ST:NEXAM
|
Sweden | Skr57.20 Million |
|
George Kent (Malaysia) Bhd
KLSE:3204
|
Malaysia | RM238.77 Million |
|
Concraft Holding Co Ltd
TW:4943
|
Taiwan | NT$2.75 Billion |
|
Radana Bhaskara Finance Tbk
JK:HDFA
|
Indonesia | Rp3.07 Trillion |
Liability Composition Analysis (2021–2025)
This chart breaks down Lite Strategy, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LITS market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lite Strategy, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lite Strategy, Inc. (2021–2025)
The table below shows the annual total liabilities of Lite Strategy, Inc. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $1.35 Million | -83.79% |
| 2024-06-30 | $8.36 Million | -91.31% |
| 2023-06-30 | $96.19 Million | -23.31% |
| 2022-06-30 | $125.43 Million | +0.64% |
| 2021-06-30 | $124.63 Million | -- |
About Lite Strategy, Inc.
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.